The Institute for Clinical and Economic Review's (ICER) latest report encourages manufacturers of extended-release medications for addiction treatment to align their prices with the drug's clinical value, InsideHealthPolicy reports. ICER in its report also pushes payers and lawmakers to avoid […]
ICER Seeks Nominations for Independent Review Groups
The Institute for Clinical and Economic Review (ICER) announced Wednesday, Dec. 5, that it was seeking nominations for its three independent evidence review groups. Nominations are sought for all three of the following groups:The California Technology Assessment Forum (CTAF); The Midwest […]
CVS Caremark Pushes Forward with QALYs Despite Patient Groups’ Criticism
CVS Caremark's decision to use the Institute for Clinical and Economic Review's $100,000 per quality-adjusted life year (QALY) threshold has created concern among some patient groups that call the practice discriminatory, but the health care giant is pushing forward. In open open letter to CVS in […]
ICER Names Athelia Tilson as VP of Development
The Institute for Clinical and Economic Review (ICER) on Thursday, Nov. 29, announced the appointment of Athelia "Tia" Tilson, formerly of Ariadne Labs, as its first vice president of development. According to a press release, Tilson will spearhead fundraising initiatives, "connecting philanthropic […]
ICER Releases Draft Scoping Document for Peanut Allergy Treatments
The Institute for Clinical and Economic Review (ICER) on Nov. 20 released a new report outlining a planned review of the comparative clinical effectiveness and value of peanut allergy therapies. According to a press release, the review will assess two treatments: DBV Technologies' Viaskin Peanut […]
ICER Releases Report on Therapies for Long-term Prophylaxis HAE
The California Technology Assessment Forum, an Institute for Clinical and Economic Review (ICER) independent committee, found that there was little evidence to distinguish between the impact of C1 inhibitors Cinryze and Haegarda for long-term prophylaxis against hereditary angiodema attacks, […]
ICER Report Assesses Value of Biologics for Asthma
The Institute for Clinical and Economic Review on Tuesday, Nov. 13, released a report on the comparative clinical effectiveness and value of biologic treatments for asthma associated with type 2 inflammation and/or allergic asthma. According to a press release, the report assesses the following […]
AveXis Stands By High Cost, One-Time SMA Therapy
AveXis President Dave Lennon is standing behind the company's high-cost, once-and-done SMA therapy, AVXS-101. According to an Endpoint News report, Lennon said the treatment could be justifiably priced between $4 million and $5 million. "Four million dollars is a significant amount of money, but […]
Blog: Should Value of Drug Hinge on Disease or Population it Treats?
One of the key questions facing the Institute for Clinical and Economic Review is whether the value of a drug should be influenced by the diseases and patient population it treats, according to a blog published on Health Affairs. While some surveys suggest people are interested in seeing the […]
ICER Releases Document Outlining Planned Review of Esketamine
The Institute for Clinical and Economic Review on Wednesday, Oct. 31, released a draft scoping document which lays out its planned review of Janssen's esketamine. Esketamine is under review by the Food and Drug Administration for treatment-resistant depression, and is expected to be approved some […]
